Evolving Standards in Multiple Myeloma Management: Critical Updates From the 2025 NCCN Guidelines : Episode 1
Opinion
Video
Early Intervention and Personalized Frontline Therapies in Multiple Myeloma
Author(s):
A panelist discusses how clinicians are navigating the evolving landscape of multiple myeloma treatment, from considering early intervention in high-risk smoldering cases to personalizing initial therapy choices between triplet and quadruplet regimens.
Video content above is prompted by the following:
- How are you approaching patients with high-risk smoldering multiple myeloma, particularly in considering early intervention before traditional CRAB (hypercalcemia, renal dysfunction, anemia, bone disease) criteria are met?
- What is your approach to personalizing first-line therapy selection among VRd (bortezomib, lenalidomide, and dexamethasone), KRd (carfilzomib, lenalidomide, and dexamethasone), and Dara-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone), considering the emerging quadruplet regimens?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
